壳聚糖纳米粒增强难溶性卡维地洛的口服生物利用度:优化及药代动力学研究。

Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study.

机构信息

School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshshila Campus, Indore, India; School of Pharmacy and Technology Management, SVKM's NMIMS, Shirpur Campus, India.

School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshshila Campus, Indore, India.

出版信息

Int J Biol Macromol. 2019 Aug 15;135:246-260. doi: 10.1016/j.ijbiomac.2019.05.162. Epub 2019 May 23.

Abstract

A major challenge associated with the oral delivery of anti-hypertensive drugs is their poor water solubility and low oral bioavailability. Carvedilol (CAR), a potential beta-blocker is hydrophobic drug that exhibit limited therapeutic effect through oral conventional drug delivery systems. For this reason, it is prerequisite to further investigate and develop an alternative drug delivery system so as to improve therapeutic efficacy of carvedilol as well as to minimize side effects of conventional treatment therapy. In the present study, it was aimed to develop nanoparticles (NPs) of a hydrophobic antihypertensive agent, Carvedilol by using chitosan (CS) as biodegradable polymer. Carvedilol chitosan nanoparticles (CAR-CS-NPs) were prepared by ionic gelation technique using sodium tripolyphosphate (TPP) as a crosslinking agent. The NPs were optimized and validated by Box-Behnken design (BBD). The optimized formulation showed particle size 102.12 nm and drug entrapment efficiency 71.26 ± 1.16%. The drug release profile of CAR-CS NPs showed biphasic release pattern with an initial burst release in the first 2 h followed by a controlled release over a period of 72 h. The pharmacokinetic results revealed that the optimized chitosan nanoparticles formulation have higher bioavailability than marketed tablet formulation which indicates CAR-CS NPs as an effective strategy to delivery poorly water soluble drugs.

摘要

与抗高血压药物的口服递送相关的一个主要挑战是它们的水溶性差和口服生物利用度低。卡维地洛(CAR)是一种有潜力的β受体阻滞剂,是一种疏水性药物,通过口服常规药物递送系统表现出有限的治疗效果。出于这个原因,有必要进一步研究和开发替代药物递送系统,以提高卡维地洛的治疗效果,并最大程度地减少常规治疗的副作用。在本研究中,旨在通过使用壳聚糖(CS)作为可生物降解的聚合物来开发疏水性抗高血压药物卡维地洛的纳米颗粒(NPs)。采用三聚磷酸钠(TPP)作为交联剂,通过离子凝胶技术制备卡维地洛壳聚糖纳米颗粒(CAR-CS-NPs)。通过 Box-Behnken 设计(BBD)对 NPs 进行优化和验证。优化的配方显示粒径为 102.12nm,药物包封效率为 71.26±1.16%。CAR-CS-NPs 的药物释放曲线显示出双相释放模式,在前 2h 内有初始突释,随后在 72h 内进行控制释放。药代动力学结果表明,优化的壳聚糖纳米颗粒配方比市售片剂配方具有更高的生物利用度,这表明 CAR-CS-NPs 是一种递送难溶性药物的有效策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索